Physician profile
Harvey Berman
NPI 1265479943
$10,645.97
in general payments reported to CMS, 2019-2025
15 companies · $833 in 2025
The $833 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,824 · 2020: $852 · 2021: $1,379 · 2022: $2,008 · 2023: $1,850 · 2024: $901 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,555.64 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,290.82 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $1,710.11 | 2019-2023 | Invega Sustenna |
| Allergan, INC. | $1,427.98 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $886.06 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $794.02 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $566.84 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $485.83 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $372.53 | 2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $271.45 | 2022-2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $246.83 | 2022-2023 | Rexulti |
| Alkermes, INC. | $125.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $124.55 | 2019 | |
| Neurocrine Biosciences, INC. | $123.11 | 2021 | |
| Corium, LLC | $121.83 | 2023 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvey Berman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.